Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Matthew M. Gubin(Washington University in St. Louis), Xiuli Zhang(Washington University in St. Louis), Heiko Schuster(German Cancer Research Center), Étienne Caron(ETH Zurich), Jeffrey P. Ward(Washington University in St. Louis), Takuro Noguchi(Washington University in St. Louis), Yulia Ivanova(Washington University in St. Louis), Jasreet Hundal(Washington University in St. Louis), Cora D. Arthur(Washington University in St. Louis), Willem-Jan Krebber(ISA Pharmaceuticals (Netherlands)), Gwenn E. Mulder(ISA Pharmaceuticals (Netherlands)), Mireille Toebes(The Netherlands Cancer Institute), Matthew D. Vesely(Washington University in St. Louis), Samuel S.K. Lam(Washington University in St. Louis), Alan J. Korman(Bristol-Myers Squibb (Germany)), James P. Allison(The University of Texas MD Anderson Cancer Center), Gordon J. Freeman(Harvard University), Arlene H. Sharpe(Harvard University), Erika L. Pearce(Washington University in St. Louis), Ton N. Schumacher(The Netherlands Cancer Institute), Ruedi Aebersold(University of Zurich), Hans-Georg Rammensee(German Cancer Research Center), Cornelis J.M. Melief(Leiden University Medical Center), Elaine R. Mardis(Washington University in St. Louis), William E. Gillanders(Washington University in St. Louis), Maxim N. Artyomov(Washington University in St. Louis), Robert D. Schreiber(Washington University in St. Louis)
Cited by 1,981Open Access